Concepedia

Michael Gwilt

MG

Statistics

Publications

10

Citations

585

H-Index

10

Active since

1982

Affiliations

Pfizer (United Kingdom)(Current)

East Cheshire NHS Trust

Michael Gwilt is an author at Pfizer (United Kingdom) specializing in medicine, pharmacology, and pharmacodynamics.

ORCID

Publications per year

1982–1993

10

Publications

10

UK-68,798: a novel, potent and highly selective class III antiarrhythmic agent which blocks potassium channels in cardiac cells.

Michael Gwilt, John Arrowsmith, Kenneth J. Blackburn et al. · Journal of Pharmacology and Experimental Therapeutics · 1990 · 189 citations

, , +17

Calcium Channel Blocking Properties of Amlodipine in Vascular Smooth Muscle and Cardiac Muscle In Vitro: Evidence for Voltage Modulation of Vascular Dihydropyridine Receptors

Roger A. Burges, Donald G. Gardiner, Michael Gwilt et al. · Journal of Cardiovascular Pharmacology · 1987 · 128 citations

, , +11

Selective class III antiarrhythmic agents. 1. Bis(arylalkyl)amines

Peter E. Cross, John Arrowsmith, Geoffrey N. Thomas et al. · Journal of Medicinal Chemistry · 1990 · 64 citations

, , +17

Lambert-Eaton myasthenic syndrome: electrophysiological evidence for a humoral factor.

John Newsom–Davis, Nicholas Murray, D. Wray et al. · PubMed · 1982 · 51 citations

, , +13

Electrophysiologic Properties of UK-66,914, a Novel Class III Antiarrhythmic Agent

Michael Gwilt, H. W. Dalrymple, Roger A. Burges et al. · Journal of Cardiovascular Pharmacology · 1991 · 38 citations

, , +17

1–5 of 10